Plain-English translation of NCT07154394 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers are investigating whether amyloid — a sticky protein that builds up in the brains of people with Alzheimer's disease — also accumulates in the heart and causes heart problems. This study will use specialized imaging scans to look for amyloid deposits in both the heart and brain of people being evaluated for Alzheimer's disease. Understanding this connection could help doctors better diagnose and treat both conditions.
Doctors know that amyloid deposits damage the brain in Alzheimer's disease, but they don't yet know if the same protein also damages the heart in these patients. This trial exists to fill that gap and potentially improve how we diagnose and care for people with both memory problems and heart issues.
You likely qualify if…
You likely don't qualify if…
If you qualify, you'll have imaging scans of your heart that use the same amyloid tracer already planned for your brain evaluation — no extra radiation or injections needed. You'll also receive an ultrasound of your heart (echocardiogram), an electrical heart tracing (EKG), and a clinical evaluation of your memory and thinking. The additional heart imaging happens at the same time as your scheduled brain scan, making it convenient and straightforward.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
Germany
Enrollment target
~15 participants
Started
August 2022
Primary completion
August 2023
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in September 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
David Kersting, MD PhD
University Hospital, Essen
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.